Fig. 3: MYCN transcriptionally upregulates ELAVL3 expression.

a ChIP-seq enrichment of MYCN at ELAVL3 and ELAVL4 promoter in prostate cancer cell lines (three independent samples; GSE117306²⁸). b MYCN binding motifs exist on ELAVL3 promoter across species. c Relative luciferase activities driven by full-length or indicated segments of ELAVL3 promoter in HEK293T (n = 3 independently transfected replicates per condition). d ChIP-qPCR of different locations on ELAVL3 promoter from LNCaP/MYCN with either MYCN antibody or IgG (three independent samples). e Relative luciferase activities driven by wildtype or indicated mutant Segment A of ELAVL3 promoter reporters in HEK293T (n = 3 independently transfected replicates per condition). f QPCR showing changes of nascent ELAVL3 mRNA in HEK293T with/without MYCN induction (n = 3 biologically independent experiments). The sgRNAs were designed to target the MYCN binding sites in the ELAVL3 promoter region and the non-targeting sgRNA was used as control. Data presented as mean ± s.e.m. (c, d, e, f). Statistical significance was determined by two-tailed unpaired Student’s t-test (c, d, e, f). BS, binding site. Source data are provided as a Source Data file.